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An Unusual Presentation of Renal Cell Carcinoma with Tumor Thrombus
Joon Soo Kim, Paul Gribben, Jennifer Fillaus

Mentor: Jennifer Fillaus
Program: Nephrology
Renal cell carcinoma (RCC) is the most
common primary renal neoplasm. Here we
present a patient with a 3 month onset of
lower extremity swelling and worsening
renal function found to be due to advanced
RCC with extensive tumor burden and rapid
subsequent decline.
A middle-aged patient was referred to
nephrology clinic for proteinuria and an
elevated creatinine from a baseline of 0.9
to 1.5mg/dL over three months. The patient
complained of bilateral leg swelling, shortness

of breath, weakness, five-pound weight loss
over the last 3 months. Vital signs were
unremarkable. Physical examination was
notable for 2+ bilateral ankle edema. CMP
was unremarkable except for a creatinine
of 1.5mg/dL and alkaline phosphatase of
581U/L (100U/L three months ago). Urine
protein/creatinine ratio was 4.29. Blood
electrophoresis with immunofixation and
free light chain ratio were all within normal
range. The patient had normocytic anemia
(Hgb 9.8mg/dL), iron saturation of 10%.
Renal ultrasound revealed a thickened left
renal cortex and poorly visualized left renal
vein. Subsequent imaging revealed a 6cm

left renal mass with tumor thrombus in the
left renal vein with extension into the IVC
from the iliac vein bifurcation to the right
atrium. A lytic lesion was noted in the L2
spine. A biopsy of the lytic lesion revealed
metastatic clear cell RCC. The patient rapidly
deteriorated from obstructive shock, acute
renal failure, significant acidosis, congestive
hepatopathy, and transudative ascites (with no
tumor cells).
RCC should always be a part of the
differential diagnosis when evaluating leg
swelling, proteinuria, or elevated creatinine. 
https://doi.org/10.32873/unmc.dc.gmerj.1.1.071
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Introduction: C3 glomerulonephritis (C3GN)
is a glomerular disease caused by excessive
activation of the alternative complement
pathway and often leads to end-stage renal
disease. Following kidney transplantation,
the recurrence risk is high and may cause
premature allograft failure. Eculizumab
prevents the membrane attack complex
(MAC) formation and provides terminal
complement inhibition. Here we present a
case of early recurrent post-transplant C3GN
in a patient with a C3 gene mutation that was
successfully treated with eculizumab.
Case Description: A middle-aged patient
with a history of chronic kidney disease
received a living unrelated kidney transplant.
Prior to the transplant, the patient was

diagnosed with C3GN which was refractory
to corticosteroids, mycophenolate, and
rituximab. Evaluation revealed a C3 gain of
function mutation. Complement inhibitory
factors were normal and the patient did not
have a C3 nephritic factor. An elevated level
of soluble MAC (sMAC) was noted prior to
transplantation. The patient had immediate
graft function following transplant and was
maintained on tacrolimus, mycophenolate,
and prednisone following basiliximab
induction. The patient’s creatinine reached a
nadir of 1.1 mg/dl, but he/she developed early
acute allograft dysfunction and proteinuria
within the first few weeks of transplant and
biopsy revealed early recurrence of C3GN.
The patient was treated with high dose
corticosteroids and plasmapheresis, but
continued progression of renal dysfunction
with rising sMAC levels, proteinuria, and

activity of C3GN on a repeat biopsy. After
initiation of eculizumab, the sMAC levels
normalized, proteinuria resolved, and the
allograft function improved. The patient is
now >1 year out from transplantation with
stable allograft function and no evidence of
complications related to the eculizumab.
Discussion: Eculizumab appears to have a
role in select patients with recurrent C3GN.
Since not all patients with C3GN improve
with eculizumab, more research is needed to
define patients expected to benefit from this
therapy. Patients with recurrent C3GN due
to a gain of function mutation in the C3 gene
should be considered for early eculizumab
therapy to preserve allograft function and
decrease excessive complement activity. 
https://doi.org/10.32873/unmc.dc.gmerj.1.1.072

Timing and Sequence of Chemoradiation for Low-Grade Gliomas Meeting RTOG 9802 Criteria
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Purpose: Radiation Therapy Oncology Group
(RTOG) 9802 has established postoperative
radiotherapy (RT) and chemotherapy
sequentially as the new standard of care for
patients with high-risk low grade glioma
(LGG) meeting trial criteria. Although all
patients in the trial received sequential
chemoradiation therapy (sCRT) with RT
followed by chemotherapy, it is unknown
whether concurrent chemoradiation therapy
(cCRT) may offer advantages over sCRT.
Methods: The National Cancer Database
(NCDB) was queried for newly-diagnosed
World Health Organization (WHO) grade II

59

glioma. Patients with unknown surgery, RT,
or chemotherapy status were excluded, along
with patients <40 years old who underwent
gross total resection to coincide with RTOG
9802 exclusion criteria. Chi squared, Fisher’s
exact or Wilcoxon rank-sum tests evaluated
differences in characteristics between groups.
Kaplan-Meier analysis was used to evaluate
overall survival (OS) between groups
(sCRT vs. cCRT). Cox proportional hazards
modeling determined variables associated
with OS.

associated with worse overall survival (OS)
on multivariable analysis included advanced
age (p<0.001) while mixed glioma (p=0.017)
and oligodendroglioma (p=0.005) were
associated with better OS than astrocytoma
histologies.
Conclusions: This is the only known analysis
of cCRT versus sCRT for LGG. There is no
evidence that cCRT improves outcomes over
sCRT. 
https://doi.org/10.32873/unmc.dc.gmerj.1.1.073

Results: In total, 496 patients were analyzed
(n=416 [83.9%] cCRT, n=80 [16.1%] sCRT).
Sequencing or concurrency of therapy did
not independently influence survival on
univariable/multivariable analysis. Factors
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